Literature DB >> 9131520

Information for patients about inflammatory bowel disease.

J C Mansfield1, A R Tanner, M G Bramble.   

Abstract

In inflammatory bowel disease it is important that patients understand their condition since this helps to improve long-term management of the disease. The aim of this study was to assess the information given to patients with inflammatory bowel disease about their condition, its treatment and the National Association for Colitis and Crohn's disease. Two surveys were performed, using anonymous questionnaires. One was of all association members in north-east England, the other was a sample of patients attending medical outpatients. The surveys showed that more patients heard of the National Association for Colitis and Crohn's disease from the media than from medical sources. Of patients seen in medical clinics, 75% would welcome more information about their disease. In four of the six participating centres less than half the patients had been told about the existence of a patients' association. There was considerable variation in the instructions on what action to take in the event of a relapse. These findings suggest that the opportunity offered by out-patient clinics to educate and inform patients is often wasted. Clinicians often neglect to mention the National Association for Colitis and Crohn's disease, especially to patients with long-standing disease. A higher priority should be given to providing patients with appropriate information on inflammatory bowel disease. Three simple audit standards for the organisation of outpatient clinic information are proposed.

Entities:  

Mesh:

Year:  1997        PMID: 9131520      PMCID: PMC5420884     

Source DB:  PubMed          Journal:  J R Coll Physicians Lond        ISSN: 0035-8819


  8 in total

Review 1.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

2.  The information needs and preferences of persons with longstanding inflammatory bowel disease.

Authors:  Samantha Wong; John R Walker; Rachel Carr; Lesley A Graff; Ian Clara; Stephen Promislow; Linda Rogala; Norine Miller; Patricia Rawsthorne; Charles N Bernstein
Journal:  Can J Gastroenterol       Date:  2012-08       Impact factor: 3.522

3.  Does better disease-related education improve quality of life? A survey of IBD patients.

Authors:  S Verma; H H Tsai; M H Giaffer
Journal:  Dig Dis Sci       Date:  2001-04       Impact factor: 3.199

4.  Childhood inflammatory bowel disease: parental concerns and expectations.

Authors:  A-S Day; K-E Whitten; T-D Bohane
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

5.  A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease.

Authors:  A P Kennedy; E Nelson; D Reeves; G Richardson; C Roberts; A Robinson; A E Rogers; M Sculpher; D G Thompson
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

6.  Patients' experiences of an open access follow up arrangement in managing inflammatory bowel disease.

Authors:  A Rogers; A Kennedy; E Nelson; A Robinson
Journal:  Qual Saf Health Care       Date:  2004-10

7.  Disease-related information requirements in patients with Crohn's disease.

Authors:  Qiangqiang Wu; Jie Zhong
Journal:  Patient Prefer Adherence       Date:  2018-08-27       Impact factor: 2.711

8.  Information Needs and Concerns of Patients with Inflammatory Bowel Disease: What Can We Learn from Participants in a Bilingual Clinical Cohort?

Authors:  Valérie Pittet; Carla Vaucher; Michel H Maillard; Marc Girardin; Philippe de Saussure; Bernard Burnand; Gerhard Rogler; Pierre Michetti
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.